BioCardia, Inc. (BCDA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BCDA
- Company BioCardia, Inc.
- Price $1.11
- Changes Percentage -11.2
- Change -0.14
- Day Low $1.1
- Day High $1.26
- Year High $2.29
- Year Low $0.75
- Market Cap $15,033,143
- Price Avg 50 EMA (D) $0.95
- Price Avg 200 EMA (D) $1.15
- Exchange NASDAQ
- Volume 81,363
- Average Volume 3,099,606
- Open $1.25
- Previous Close $1.25
- EPS -0.91
- PE -1.11
- Earnings Announcement 2026-11-11 05:00:00
- Shares Outstanding $14,884,300
Company brief: BIOCARDIA, INC. (BCDA )
- Healthcare
- Biotechnology
- Dr. Peter A. Altman Ph.D.
- https://www.biocardia.com
- US
- N/A
- 11-13-1996
- US09060U5074
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.